Jonathan David Schwartz - 17 Feb 2023 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Role
Chief Medical Officer & Clinical Development, SVP
Signature
/s/ Martin Wilson, as attorney-in-fact for Jonathan David Schwartz
Issuer symbol
RCKT
Transactions as of
17 Feb 2023
Net transactions value
-$67,796
Form type
4
Filing time
22 Feb 2023, 18:28:17 UTC
Previous filing
22 Feb 2023
Next filing
13 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCKT Common Stock Sale $67,796 -3,557 -3.6% $19.06 94,546 17 Feb 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person.
F2 This transaction was executed in multiple brokered trades at prices ranging from $18.735 to $19.195. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

Chief Medical Officer & Clinical Development, SVP